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SUMMARY – The aim of this study was to assess the Croatian urologists’ management of 
non-neurogenic male lower urinary tract symptoms (LUTS) and their compliance with the Euro-
pean Association of Urology (EAU) guidelines. A cross-sectional survey included 51/179 Croatian 
urologists. We developed a questionnaire with questions addressing compliance with EAU guide-
lines. The rate of performing recommended evaluations on the initial assessment of patients with 
benign prostate hyperplasia (BPH)/LUTS varied from 8.0% (serum creatinine and voiding diary) to 
100.0% (physical examination, prostate specific antigen and ultrasound). The international prostate 
symptom score was performed by 31%, analysis of urine sediment by 83%, urine culture by 53%, and 
serum creatinine by 8% of surveyed urologists. Only 8% of urologists regularly used bladder diary 
in patients with symptoms of nocturia. Our results indicated that 97% of urologists preferred alpha 
blockers as the first choice of treatment; 5-alpha reductase inhibitors (5ARI) were mostly prescribed 
(84%) in combination with an alpha-blocker, preferably as a continuous treatment, whilst 29% of 
urologists used to discontinue 5ARI after 1-2 years. Half of the Croatian urologists used antimusca-
rinics in the treatment of BPH/LUTS and recommended phytotherapeutic drugs in their practice. 
In conclusion, Croatian urologists do not completely comply with the guidelines available.
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Introduction
Lower urinary tract symptoms (LUTS) repre-
sent one of the most common clinical complaints in 
adult men and are commonly yet not exclusively re-
lated to benign prostate hyperplasia (BPH)1. Require-
ments for greater consistency and quality in patient 
care prompted the European Association of Urology 
(EAU) to create and update clinical practice guide-
lines for LUTS. Clinical practice guidelines aim to 
improve the quality of patient care by providing spe-
cific recommendations for daily practice2. The EAU 
guidelines state that as a routine part of the initial 
assessment of male LUTS, medical history must be 
taken, a validated symptom score questionnaire with 
quality of life (QoL) question(s) should be completed, 
physical examination including digital rectal exami-
nation (DRE) should be performed, urinalysis must 
be ordered, post-void residual urine (PVR) should be 
measured, and uroflowmetry may be performed. Mic-
turition frequency-volume charts or bladder diaries 
should be used to assess male LUTS with a promi-
nent storage component or nocturia. Prostate-specific 
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antigen (PSA) should be measured only if the diag-
nosis of prostate cancer will change the management, 
or if PSA can assist in decision-making in patients at 
risk of symptom progression and complications. Re-
nal function must be assessed if renal impairment is 
suspected from the history and clinical examination, 
if the patient has hydronephrosis, or when consider-
ing surgical treatment for male LUTS. Uroflowmetry 
should be performed before any treatment. Imaging 
of the upper urinary tract in men with LUTS should 
be performed in patients with large PVR, hematuria, 
or a history of urolithiasis. Imaging of the prostate 
should be performed if it assists in choosing an appro-
priate drug and when considering surgical treatment. 
Urethrocystoscopy should only be performed in men 
with LUTS to exclude suspected bladder or urethral 
pathology and/or before minimally invasive/surgical 
therapies if the findings may change the treatment. 
Pressure-flow studies should be performed only in 
individual patients for specific indications before sur-
gery or when evaluation of the pathophysiology un-
derlying LUTS is warranted2.
In the present study, we aimed to examine the 
Croatian urologists’ clinical practice and their com-
pliance with EAU guidelines on the management of 
BPH/LUTS. We hypothesized that urologists were 
not uniformly adherent to the guidelines in evaluating 
a new patient with BPH related LUTS. The results 
would enlighten further study of barriers to adher-
ence.
Subjects and Methods
This cross-sectional study was designed as an elec-
tronic tele voting survey including 51 Croatian urolo-
gists. We constructed a questionnaire to explore the 
clinical practice and compliance with guidelines. As 
the questionnaire contained relatively simple ques-
tions, it was pilot-tested for understanding. The pilot 
testers easily understood the questions, so no changes 
were made, and these data were not included in the 
analysis. The survey contained 2 sections. Section I 
assessed preferences in the recommended diagnostic 
tests. The survey included ten questions regarding the 
use of specific diagnostic tools in the assessment of 
LUTS patients according to EAU guidelines. The re-
spondents answered whether or not they used history, 
DRE, International Prostate Symptom Score (IPSS), 
urine analysis, urine culture, PSA, uroflowmetry, 
voiding diary and ultrasound on the initial assessment 
of LUTS. Further, they answered if they ever ordered 
urodynamics in these settings. Section II questions 
referred to initial therapy, treatment practice and their 
compliance with EAU recommendations. Questions 
referred to first option treatment, combination treat-
ment with 5-alpha reductase inhibitors (5ARI)  and 
its duration, combination with 5 phosphodiesterase 
inhibitors when erectile dysfunction occurs, use of 
antimuscarinics and phytotherapy. In addition, urolo-
gists were asked to rate their perceived adherence (yes 
or no) with diagnostic and treatment recommenda-
tions in LUTS patients. Cohort characteristics are 
depicted in Table 1.
Table 1. Cohort characteristics
n %
Age <40 years 25 49.1
>40 years 26 50.9
Sex Male 48 94.1
Female 3  5.9
Workplace University hospital 28 54.9
County hospital 20 39.2
Private practice 3 5.9
Statistical analysis 
Descriptive statistics was used to describe demo-
graphic and professional characteristics of the cohort 
(mean, standard deviation, percentage). Results were 
expressed as percent agreement with the questions/
statements in the questionnaire. 
Results 
The study included 51/179 (28%) urologists in 
Croatia, 48/51 male and three female, mean age 
45±6.3 (range, 30-65) years. Forty-eight urologists 
work in hospital settings and three in private practice. 
Twenty-eight urologists work in university hospitals 
and the rest in county or general hospitals. The rate of 
performance of recommended evaluations varied from 
8.0% (serum creatinine and voiding diary) to 100.0% 
(physical examination, PSA and ultrasound). Com-
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plete results are shown in Figure 1. The rate of perfor-
mance of not routinely recommended measures such 
as urodynamics was 8%. Questions regarding obliga-
tory and optional tools in the assessment of LUTS 
patients according to EAU guidelines and respective 
answers are shown in Table 1. Initial assessment of 
LUTS/BPO (benign prostatic obstruction) comprised 
clinical interview and DRE, as well as PSA and ul-
trasound performed by all urologists (100%), IPSS by 
31%, urine sediment/dipstick test by 83%, urine cul-
ture by 53%, serum creatinine by 8%, uroflowmetry 
by 53%, and in case of nocturia, voiding diary by 2% 
of urologists.  
Considering drug treatment options, the pre-
ferred therapy was treatment with alpha blockers. 
Study results indicated that 97% of the urologists pre-
ferred them as first choice treatment, while 22% con-
sidered tamsulosin to reduce the risk of retention and 
need of surgical treatment at long term. Two-thirds of 
the urologists would combine phosphodiesterase type 
5 (PDE5) inhibitors (5PDEI) medication with alpha 
blockers regardless of selectivity. When prescrib-
ing  5ARI, most of the urologists (84%) prescribed 
them in combination with an alpha-blocker, prefer-
ably as a continuous treatment, whilst 29% used to 
discontinue 5ARI after 1-2 years. Half of the Croa-
tian urologists used antimuscarinics in the treatment 
of BPH/LUTS and 57% recommended phytothera-
peutic drugs in their practice. The perceived level of 
compliance with EAU guidelines and summary of 
therapeutic approach are illustrated in Figure 2.
Discussion
The purpose of this study was to assess clinical 
practice and compliance with EAU guidelines among 
specialists in urology in Croatia by focusing on the 
key recommendations from the guidelines. Our in-
vestigation included one of the most comprehensive 
analyses of urologists’ adherence to EAU guidelines 
on the management of BPH/LUTS in one country, 
and to our knowledge, is the first published analysis 
of the rate of performing the recommended measures 
in Croatia. Interestingly, Croatian urologists observe 
guidelines when it comes to history and physical 
examination, but obligatory tests such as validated 
symptom score questionnaire or urinalysis are not 
uniformly performed. Half of them would order urine 
culture on the initial assessment but do not think 
that it should be routinely performed. On the con-
trary, tests such as PSA, which should be performed 
only if the findings change the practice, are uniformly 
performed by all urologists. Furthermore, some tests 
indicated in specific circumstances such as voiding 
DRE = digital rectal examination; IPSS = international symptom 
score; PSA = prostate specific antigen
Fig. 1. Percentage of Croatian urologists using routinely/
not routinely the measures recommended by the European 
guidelines on initial patient evaluation for benign pros-
tate hyperplasia/lower urinary tract symptoms.
AB = alpha blockers; 5ARI = 5 alpha reductase inhibitors; the 
last columns represent perceived adherence to the European 
Association of Urology guidelines by urologists themselves
Fig. 2. Croatian urologists’ therapeutic approach to benign 
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diary in nocturia are rarely performed. Optional test 
uroflowmetry is initially ordered by half of the urolo-
gists. Renal function is initially rarely assessed. When 
it comes to therapy, alpha blockers are the first choice 
treatment for most of the urologists, which is consis-
tent with practice in most countries, but surprisingly 
22% of the urologists wrongly believe that they can 
reduce the risk of urinary retention or need of surgery. 
Strikingly, half of the Croatian urologists prescribe 
phytotherapy, although there is no specific recom-
mendation in the guideline panel regarding this ther-
apy2. The aim of the guidelines is to provide a guide 
and an authoritative reference on the most appropriate 
clinical pathway currently available. However, pub-
lication of guidelines does not necessarily influence 
clinical practice. Passive dissemination is generally 
ineffective in changing physicians’ behavior3. Despite 
considerable efforts in developing and implementing 
evidence-based guidelines, only modest impact on 
clinical practice has been observed4-7. Some data sug-
gest that only about half of the patients (55%) received 
recommended care as described in the guidelines8. 
Despite great efforts to promote and support guide-
line use, adherence is often suboptimal. There might 
be various reasons for disregarding the guidelines. In a 
recent study on imaging in prostate cancer, Simonato 
et al. concluded that urologists probably knew that 
such guidelines existed, but in everyday practice they 
were not consulted, probably due to limited time and 
pressure of work, so that guidelines do not enter com-
mon clinical practice9. There are only few articles in 
the literature on the utility of BPH/LUTS guidelines 
in everyday clinical practice. Auffenberg et al. investi-
gated the rate of physician adherence to the American 
Urologic Association guidelines on the management 
of BPH/LUTS10. They systematically evaluated a total 
of 3494 new BPH encounters between 2008 and 2012 
using electronic medical record based data in a large 
university urology practice. The rate of performance of 
recommended evaluations varied from 53.0% (docu-
mentation of IPSS) to 92.8% (performance of physi-
cal examination). The rate of performing not routinely 
recommended measures varied from 1.9% (urinary 
cytology) to 10.2% (serum creatinine measurement).
Strope et al. studied a cohort representing 5% of 
Medicare BPH/LUTS patients11. They found nearly 
15-fold variation in the urologist’s average per patient 
expenditures ($35 to $527 per month; median $92). 
Practice styles were associated with physician (p<0.01 
all examined variables) and patient (p<0.01 for comor-
bidity, race and socioeconomic status) factors.  They 
concluded that practice styles for BPH evaluations 
varied substantially according to geography, practice 
setting and experience, and accounted for large differ-
ences in the use of optional and not routinely recom-
mended tests11. Wei et al. examined the evaluation and 
management of LUTS/BPH by physician specialty 
(urologist vs. primary care physician). They found sig-
nificant differences in practice patterns between pri-
mary care physicians and urologists in the evaluation 
and management of LUTS/BPH12. 
Our study was limited by the inherent bias in-
troduced by the cross sectional design. Its strength 
though was the fact that data were collected directly 
from urologists and not from medical records or insur-
ance providers. Guidelines are at present only partially 
observed by Croatian urologists. The causes should be 
further investigated, but literature findings identify 
the possible ones, i.e. impossibility of implementing 
the recommended measures, the scope of work and 
working conditions, inadequate dissemination of in-
formation, as well as differences in routine practices, 
beliefs, costs, availability, or other13. 
Conclusion
This study provided the first analysis of Croatian 
urologist compliance with EAU guidelines on the 
management of BPH/LUTS that is based entirely on 
data collected directly from the practicing urologists 
in Croatia. Our study describes the management pat-
tern of male LUTS suggestive of BPH and shows that 
the pattern does not completely comply with available 
guidelines and the implementation of EAU clini-
cal guidelines in Croatia is not uniform. This should 
encourage more efforts to improve the awareness of 
the guidelines. Increased emphasis on guidelines in 
residency training might decrease these variations. 
Greater standardization could enhance patient care 
and reduce health care costs. Future research is neces-
sary to determine the causes that modify adherence 
rates and subsequently determine whether increased 
adherence improves patient outcomes.
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Sažetak
KLINIčKA PRAKSA HRVATSKIH UROLOGA I USKLAđENOST SA SMJERNICAMA U  LIJEčENJU 
SIMPTOMA DONJEG MOKRAćNOG TRAKTA U MUšKARACA 
I. Tomašković, M. Tomić, S. Nikles, I. Neretljak i V. Miličić
Cilj ovoga istraživanja bio je uvrditi kliničku praksu hrvatskih urologa u pristupu bolesnicima sa simptomima donjeg 
mokraćnog trakta (LUTS) i njihovo pridržavanje Smjernica Europskoga urološkog društva (EAU). Provedeno je presječ-
no istraživanje među 51/179 (28%) hrvatskih urologa. Izradili smo upitnik koji sadrži pitanja glede poštivanja smjernica 
EAU. Primjena preporučenih pretraga u početnoj procjeni bolesnika s benignom hiperplazijom prostate (BPH)/LUTS 
varirala je od 8,0% (kreatinin i dnevnik mokrenja) do 100,0% (fizikalni pregled, antigen specifičan za prostatu (PSA) i 
ultrazvuk). U početnoj procjeni bolesnika s BPH/LUTS uz anamnezu i digitorektalni pregled hrvatski urolozi primjenjuju 
još PSA i ultrazvuk (100%). Međunarodni zbroj prostatičnih simptoma (IPSS) primjenjuje 31%, analizu sedimenta mo-
kraće 83%, kulturu mokraće 53%, a serumski kreatinin 8% ispitanih urologa. Samo 8% urologa redovito koristi dnevnik 
mokrenja kod bolesnika sa simptomima nokturije. Rezultati su pokazali kako 62% hrvatskih urologa smatra da provodi 
dijagnostičku obradu koja je u skladu sa smjernicama EAU. U terapijskom pogledu rezultati pokazuju da 97% urologa 
smatra alfa blokatore lijekom prvog izbora. Inhibitori 5-alfa reduktaze (5ARI) uglavnom (84%) su propisani u kombinaciji 
s alfa-blokatorima, ponajprije kao kontinuirano liječenje, dok 29% prekida 5ARI nakon 1-2 godine. Polovica hrvatskih 
urologa rabi antimuskarinike u liječenju BPH/LUTS i preporučuje fitoterapiju u svojoj praksi. Praksa hrvatskih urologa 
nije u potpunosti usklađena sa smjernicama.
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